Bristol-Myers Squibb Company (BMY)
Automate Your Wheel Strategy on BMY
With Tiblio's Option Bot, you can configure your own wheel strategy including BMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMY
- Rev/Share 23.4545
- Book/Share 8.5908
- PB 5.5888
- Debt/Equity 2.9466
- CurrentRatio 1.2789
- ROIC 0.1085
- MktCap 97378578000.0
- FreeCF/Share 6.4431
- PFCF 7.4414
- PE 17.9338
- Debt/Assets 0.5544
- DivYield 0.051
- ROE 0.3193
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BMY | Cantor Fitzgerald | -- | Neutral | -- | $55 | April 22, 2025 |
| Initiation | BMY | Piper Sandler | -- | Overweight | -- | -- | April 22, 2025 |
| Upgrade | BMY | Jefferies | Hold | Buy | -- | $70 | Dec. 16, 2024 |
| Resumed | BMY | BofA Securities | -- | Neutral | -- | $63 | Dec. 10, 2024 |
| Initiation | BMY | Bernstein | -- | Market Perform | -- | $56 | Oct. 17, 2024 |
News
BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers' Opdivo SC wins EU approval as the first PD-1 inhibitor for subcutaneous use across multiple solid tumor indications.
Read More
Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Negative
BMY slides 20.7% in 3 months despite strong Q1 and raised outlook, as generic pressure and pipeline setbacks weigh on investor sentiment.
Read More
Bristol-Myers Squibb's Painful Pullback Has Triggered Richer Dividend Story - Upgrade To Buy
Published: May 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Bristol Myers Squibb's much needed correction has brought the stock back to earth, nearer to its 1Y means while triggering the expanded forward dividend yields. Its dividend investment thesis appears safe as well, as observed in the management's recent payout hike and the still rich cash flows despite the ongoing patent cliff impact. This is on top of the raised FY2025 guidance, given the accelerating Growth Portfolio revenue profile compared to a year ago, thanks to the M&A activities and intensified R&D efforts.
Read More
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Bristol-Myers: Among The Cheapest Pharma Names, Now Yielding Above 5%
Published: May 27, 2025 by: Seeking Alpha
Sentiment: Positive
I reiterate my buy rating on Bristol-Myers, seeing significant undervaluation despite persistent weak technicals and sector underperformance. BMY's strong earnings beats, high free cash flow yield, and nearly 6% dividend make it a compelling income play, even amid pipeline concerns. Valuation is attractive: a sub-7x forward P/E and high dividend yield more than discount muted growth and generic competition risks.
Read More
Bristol-Myers Squibb At ASCO 2025: A Resilient Play Amid Market Turbulence
Published: May 27, 2025 by: Seeking Alpha
Sentiment: Positive
Despite socio-economic challenges and pressure from the generic versions of Revlimid and Abraxane, Bristol-Myers Squibb Company's financial position continues to improve. It raised its 2025 diluted EPS guidance from $6.55-$6.85 to $6.7-$7, as well as revenue expectations from $45.5 billion to $45.8-$46.8 billion. Bristol-Myers Squibb's key franchises remain oncology and cardiovascular, primarily due to the strong performance of Opdivo, Camzyos, and Reblozyl.
Read More
When It Rains Gold, Put Out The Bucket: 2 Wonderful Income Bargains
Published: May 26, 2025 by: Seeking Alpha
Sentiment: Positive
Focus on high-quality, dividend-paying stocks with temporary setbacks, offering both value and income for patient investors. Bristol-Myers Squibb is deeply undervalued, carries a 5.3% yield, strong profitability, and a promising neurodegenerative drug pipeline. Rexford Industrial Realty offers a 5% yield, benefits from supply-constrained Southern California industrial markets, and trades far below historical valuation.
Read More
Avoid These Dividend Disasters Before It's Too Late
Published: May 23, 2025 by: Seeking Alpha
Sentiment: Negative
Dividend stocks are facing many big risks. The high interest rates, trade war, and AI revolution could lead to many dividend cuts. I discuss what this all means for dividend investors.
Read More
Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline.
Read More
Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.
Read More
Buy These 2 Beaten Down Stocks Now Before They Rally
Published: May 19, 2025 by: Seeking Alpha
Sentiment: Positive
I'm recommending two beaten-down REITs, American Assets Trust and Alexandria Real Estate, as long-term dividend plays with strong fundamentals and well-covered yields. Both stocks face near-term headwinds, but offer attractive entry points for patient investors seeking multi-year recovery and income. AAT is undervalued due to office exposure and California concentration, but has solid financials, a safe dividend, and multifamily growth potential.
Read More
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Read More
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Dividend Harvesting Portfolio Week 218: $21,800 Allocated, $2,195.04 In Projected Dividends
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Positive
Earnings season saw strong reports from Microsoft, Apple, Meta, and Amazon, boosting the S&P 500 by 2.75% and the Nasdaq by 2.82%. The Dividend Harvesting Portfolio gained 1.98% this week, with a total return of 23.42% and forward dividend income reaching $2,195.04. Added to positions in Bristol-Myers Squibb, Pfizer, and BP, focusing on undervalued stocks with strong dividend yields and growth potential.
Read More
First-Quarter GDP Halfway to Recession: Move to These Safe High-Yield Dividend Stocks Now
Published: May 01, 2025 by: 24/7 Wall Street
Sentiment: Positive
The first report for U.S. gross domestic product (GDP) came in at −0.3% as the economy contracted for the first time in three years.
Read More
This High-Yield Pharma Stock Looks Like an Incredible Bargain
Published: April 30, 2025 by: The Motley Fool
Sentiment: Positive
When markets get choppy, smart investors often seek refuge in pharmaceutical stocks. These companies typically offer consistent cash flows, essential products, and solid dividends regardless of economic conditions.
Read More
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
Published: April 26, 2025 by: The Motley Fool
Sentiment: Positive
It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong underlying operations and are generally more resilient than their non-dividend-paying counterparts.
Read More
Bristol-Myers: Undervalued, Delivering Increased 2025 Guidance
Published: April 25, 2025 by: Seeking Alpha
Sentiment: Positive
Despite recent underperformance, Bristol-Myers' strong cash position, robust pipeline, and strategic acquisitions position it for future growth, making it an undervalued opportunity. BMY's growth portfolio is thriving, with significant YoY increases in key drugs, offsetting declines in its legacy products. BMY's consistent dividend growth and strong profitability make it an attractive income investment, especially as the Fed reduces rates.
Read More
BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
BMY beats on both earnings and sales in the first quarter of 2025. The company raises its guidance for the full year.
Read More
Jobless Claims Increased in Line With Expectations
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Ahead of the opening bell this Thursday morning, Initial Jobless Claims came in at 222K for last week, slightly above estimates but certainly within range that demonstrates a continued healthy labor market. The previous week's print of 216K was ratcheted up just slightly on revision.
Read More
Bristol-Myers Squibb Company (BMY) Q1 2025 Earnings Call Transcript
Published: April 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Bristol-Myers Squibb Company (NYSE:BMY ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Chuck Triano - SVP and Head of IR Chris Boerner - Board Chair and CEO David Elkins - CFO Adam Lenkowsky - CCO Samit Hirawat - CMO and Head of Global Drug Development Conference Call Participants Chris Schott - JPMorgan Mohit Bansal - Wells Fargo Luisa Hector - Berenberg Geoff Meacham - Citi Evan Seigerman - BMO Capital Terence Flynn - Morgan Stanley Trung Huynh - UBS Courtney Breen - Bernstein Tim Anderson - Bank of America David Risinger - Leerink Partners …
Read More
Bristol-Myers Squibb Is A Good Pick
Published: April 24, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb Company is undervalued, trading 30% below its intrinsic value, with a low price-to-free-cash-flow ratio indicating a strong buying opportunity. In the first quarter, Bristol-Myers Squibb did beat expectations for revenue and earnings per share, but had to report declining sales. Management expects a revenue decline in 2025 due to legacy portfolio drops, but growth portfolio and promising pipeline offer long-term potential.
Read More
Compared to Estimates, Bristol Myers (BMY) Q1 Earnings: A Look at Key Metrics
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Bristol Myers Squibb (BMY) Surpasses Q1 Earnings and Revenue Estimates
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.80 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to loss of $4.40 per share a year ago.
Read More
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
Published: April 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
One Sector Paying Big Dividends Is Off to the Best Start in 25 Years Despite Tariffs
Published: April 18, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.
Read More
Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers is looking to turn its business around, banking on the strong uptake of new drugs. However, the 2025 outlook is not bright and we recommend investors to wait and watch for now.
Read More
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.
Read More
BMY Down on Heart Drug Camzyos Failure in Late-Stage Study
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Negative
Bristol Myers phase III study evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy fails to meet its dual-primary endpoints.
Read More
About Bristol-Myers Squibb Company (BMY)
- IPO Date 1972-06-01
- Website https://www.bms.com
- Industry Drug Manufacturers - General
- CEO Dr. Christopher S. Boerner Ph.D.
- Employees 34100